Morgan Stanley Acadia Pharmaceuticals Inc Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Morgan Stanley holds 7,297,049 shares of ACAD stock, worth $143 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,297,049

Previous 1,675,854 335.42%

Holding current value

$143 Million

Previous $25.8 Million 419.17%

% of portfolio

0.01%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$14.29 - $18.76 $80.3 Million - $105 Million	5,621,195 Added 335.42%	7,297,049 $134 Million
Q3 2024 Nov 14, 2024	SELL	$15.14 - $19.14 $10.8 Million - $13.7 Million	-715,251 Reduced 29.91%	1,675,854 $25.8 Million
Q2 2024 Oct 17, 2024	BUY	$14.62 - $18.42 $13.6 Million - $17.1 Million	928,093 Added 63.44%	2,391,105 $38.9 Million
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $13.6 Million - $17.1 Million	928,093 Added 63.44%	2,391,105 $38.9 Million
Q1 2024 Oct 17, 2024	SELL	$17.79 - $30.86 $16.5 Million - $28.6 Million	-928,093 Reduced 38.81%	1,463,012 $27.1 Million
Q1 2024 Aug 16, 2024	BUY	$17.79 - $30.86 $1.8 Million - $3.12 Million	101,112 Added 7.42%	1,463,012 $27.1 Million
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $1.8 Million - $3.12 Million	101,112 Added 7.42%	1,463,012 $27.1 Million
Q4 2023 Aug 16, 2024	SELL	$20.78 - $31.77 $21.4 Million - $32.7 Million	-1,029,205 Reduced 43.04%	1,361,900 $42.6 Million
Q4 2023 Feb 13, 2024	SELL	$20.78 - $31.77 $10.3 Million - $15.7 Million	-494,480 Reduced 26.64%	1,361,900 $42.6 Million
Q3 2023 Nov 15, 2023	SELL	$20.84 - $33.47 $39 Million - $62.6 Million	-1,871,600 Reduced 50.2%	1,856,380 $38.7 Million
Q2 2023 Aug 14, 2023	SELL	$17.8 - $25.65 $3.32 Million - $4.79 Million	-186,724 Reduced 4.77%	3,727,980 $89.3 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $19.1 Million - $24.5 Million	1,169,966 Added 42.63%	3,914,704 $73.7 Million
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $4.63 Million - $6.08 Million	-326,375 Reduced 10.63%	2,744,738 $43.7 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $690,811 - $894,480	-48,959 Reduced 1.57%	3,071,113 $50.2 Million
Q2 2022 Oct 27, 2022	BUY	$13.01 - $27.22 $28.4 Million - $59.3 Million	2,179,690 Added 231.79%	3,120,072 $44 Million
Q2 2022 Aug 15, 2022	BUY	$13.01 - $27.22 $28.4 Million - $59.3 Million	2,179,690 Added 231.79%	3,120,072 $44 Million
Q1 2022 Oct 27, 2022	SELL	$20.94 - $27.5 $45.6 Million - $59.9 Million	-2,179,690 Reduced 69.86%	940,382 $22.8 Million
Q1 2022 May 13, 2022	BUY	$20.94 - $27.5 $5.82 Million - $7.64 Million	277,723 Added 41.91%	940,382 $22.8 Million
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $2.66 Million - $4.3 Million	-158,584 Reduced 19.31%	662,659 $15.5 Million
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $13 Million - $20.3 Million	821,243 New	821,243 $13.6 Million

Others Institutions Holding ACAD

# of Institutions

316

Shares Held

164M

Call Options Held

855K

Put Options Held

350K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.17B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account